by MM360 Staff | Sep 11, 2025 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by MM360 Staff | Sep 7, 2025 | Uncategorized
Source: CureToday articles Data from the AQUILA study support the use of fixed-duration subcutaneous Darzalex Faspro as an early treatment option in high-risk smoldering myeloma. Read More
by MM360 Staff | Sep 3, 2025 | Publications
ESMO Open. 2025 Aug;10(8):105514. doi: 10.1016/j.esmoop.2025.105514. Epub 2025 Jul 15. ABSTRACT BACKGROUND: The treatment landscape for relapsed/refractory multiple myeloma (RRMM) is rapidly evolving, particularly for patients exposed or refractory to lenalidomide....
by MM360 Staff | Sep 3, 2025 | Myeloma News
Source: Pharmacy Times articles Subcutaneous bortezomib shows fewer adverse effects in multiple myeloma treatment compared to intravenous administration, enhancing patient outcomes. Read More
by MM360 Staff | Sep 2, 2025 | Myeloma News
Source: Pharmacy Times articles For pharmacists, understanding the evolving therapeutic landscape is essential—not only to optimize drug selection and dosing but also to counsel patients on complex regimens, manage adverse effects, and monitor for treatment-related...